Health Discovery Corporation (OTCBB: HDVY) is pleased to announce that a request for reexamination of Intel Corporation’s U.S. Patent No. 7,685,077 was filed this week in the United States Patent and Trademark Office. The request challenges Intel’s alleged rights to the RFE-SVM method as claimed in their patent entitled “Recursive Feature Eliminating Method Based on a Support Vector Machine.” The challenge is based upon the failure of the Patent Office to properly consider relevant prior art during the original examination of Intel’s patent application. This prior art includes the original 2002 publication by Guyon, Weston, Barnhill and Vapnik, which first described the RFE-SVM method, prior published patent applications of HDC, and published articles by others who reference the 2002 Guyon et al. paper, all of which predate the filing date of the Intel application.
In accordance with Patent Office rules, the filing of the request for reexamination was accompanied by written notice to Intel that the validity of its patent is being challenged. This represents the first direct notice to Intel of the Company’s prior rights in the RFE-SVM technology. The Company expects this notice to be followed shortly by notification of Intel by the U.S. Patent Office that interference proceedings have been initiated involving the same patent.
The value of the Company’s RFE-SVM technology is underscored by the identification of recently-published patent applications by several commercial entities and research institutions describing the use of RFE-SVM for various purposes. The published applications include one filed by Intel describing a smart phone sensor that uses SVM and RFE-SVM to analyze sensor input.
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relating to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop or commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.